TY - JOUR
T1 - Sunitinib malate in the treatment of renal cell carcinoma and gastrointestinal stromal tumor
T2 - Recommendations for patient management
AU - Desai, Jayesh
AU - Gurney, Howard
AU - Pavlakis, Nick
AU - Mcarthur, Grant A.
AU - Davis, Ian D.
PY - 2007/12/1
Y1 - 2007/12/1
N2 - Sunitinib malate (SU011248, Sutent®[Pfizer]) is an oral multitargeted tyrosine kinase inhibitor with efficacy against renal cell carcinoma (RCC) and gastrointestinal stromal tumor (GIST). Sunitinib has been approved by various regulatory authorities for treatment of advanced RCC and unresectable and/or malignant GIST following failure of imatinib mesylate treatment due to resistance or intolerance. Sunitinib is generally well tolerated, with most side-effects being mild to moderate. The most common adverse events are lethargy, diarrhea, stomatitis, hand-foot syndrome and hypertension. Uncommon but important adverse effects are hypothyroidism and hematological toxicity (neutropenia and thrombocytopenia), which require monitoring. Caution is recommended when using concurrent inhibitors or inducers of CYP3A4. The frequency and severity of side-effects often correlates with increased drug exposure. In clinical trials, side-effects seldom led to treatment discontinuation. This paper summarizes the published literature and provides recommendations for patient assessments and management of treatment-related side-effects.
AB - Sunitinib malate (SU011248, Sutent®[Pfizer]) is an oral multitargeted tyrosine kinase inhibitor with efficacy against renal cell carcinoma (RCC) and gastrointestinal stromal tumor (GIST). Sunitinib has been approved by various regulatory authorities for treatment of advanced RCC and unresectable and/or malignant GIST following failure of imatinib mesylate treatment due to resistance or intolerance. Sunitinib is generally well tolerated, with most side-effects being mild to moderate. The most common adverse events are lethargy, diarrhea, stomatitis, hand-foot syndrome and hypertension. Uncommon but important adverse effects are hypothyroidism and hematological toxicity (neutropenia and thrombocytopenia), which require monitoring. Caution is recommended when using concurrent inhibitors or inducers of CYP3A4. The frequency and severity of side-effects often correlates with increased drug exposure. In clinical trials, side-effects seldom led to treatment discontinuation. This paper summarizes the published literature and provides recommendations for patient assessments and management of treatment-related side-effects.
KW - Gastrointestinal stromal tumor (GIST)
KW - Multitargeted tyrosine kinase inhibitor (TKI)
KW - Renal cell carcinoma (RCC)
KW - Sunitinib
UR - http://www.scopus.com/inward/record.url?scp=36749047492&partnerID=8YFLogxK
U2 - 10.1111/j.1743-7563.2007.00136.x
DO - 10.1111/j.1743-7563.2007.00136.x
M3 - Review Article
AN - SCOPUS:36749047492
VL - 3
SP - 167
EP - 176
JO - Asia-Pacific Journal of Clinical Oncology
JF - Asia-Pacific Journal of Clinical Oncology
SN - 1743-7555
IS - 4
ER -